[go: up one dir, main page]

MX2019003811A - Metodos para predecir el desenlace clinico del cancer. - Google Patents

Metodos para predecir el desenlace clinico del cancer.

Info

Publication number
MX2019003811A
MX2019003811A MX2019003811A MX2019003811A MX2019003811A MX 2019003811 A MX2019003811 A MX 2019003811A MX 2019003811 A MX2019003811 A MX 2019003811A MX 2019003811 A MX2019003811 A MX 2019003811A MX 2019003811 A MX2019003811 A MX 2019003811A
Authority
MX
Mexico
Prior art keywords
cancer
methods
predicting
genes
prognosis
Prior art date
Application number
MX2019003811A
Other languages
English (en)
Other versions
MX391499B (es
Inventor
B Baker Joffre
Collin Francois
Liu Mei-Lan
T Cronin Maureen
Original Assignee
Genomic Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genomic Health Inc filed Critical Genomic Health Inc
Publication of MX2019003811A publication Critical patent/MX2019003811A/es
Publication of MX391499B publication Critical patent/MX391499B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Evolutionary Biology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención proporciona métodos para determinar el pronóstico y el tratamiento adecuado para pacientes con diagnóstico de cáncer, basándose en los niveles de expresión de uno o más biomarcadores. De manera más particular, la invención se refiere a la identificación de genes, o de conjuntos de genes, capaces de distinguir a los pacientes de cáncer de mama con buen pronóstico clínico respecto de aquellos que tienen un mal pronóstico clínico. La invención también proporciona métodos para obtener un informe genómico personalizado para un paciente de cáncer. La invención también se refiere a sistemas de computadora y software para análisis de datos utilizando los métodos de pronóstico y estadística divulgados en la presente.
MX2019003811A 2009-11-23 2010-11-19 Metodos para predecir el desenlace clinico del cancer. MX391499B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26376309P 2009-11-23 2009-11-23
PCT/US2010/057490 WO2011063274A2 (en) 2009-11-23 2010-11-19 Methods to predict clinical outcome of cancer

Publications (2)

Publication Number Publication Date
MX2019003811A true MX2019003811A (es) 2019-08-05
MX391499B MX391499B (es) 2025-03-21

Family

ID=44060376

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2016003089A MX363817B (es) 2009-11-23 2010-11-19 Métodos para predecir el desenlace clínico del cáncer.
MX2019003811A MX391499B (es) 2009-11-23 2010-11-19 Metodos para predecir el desenlace clinico del cancer.
MX2012005822A MX337650B (es) 2009-11-23 2010-11-19 Metodos para predecir el desenlace clinico del cancer.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016003089A MX363817B (es) 2009-11-23 2010-11-19 Métodos para predecir el desenlace clínico del cáncer.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2012005822A MX337650B (es) 2009-11-23 2010-11-19 Metodos para predecir el desenlace clinico del cancer.

Country Status (13)

Country Link
US (4) US20110123990A1 (es)
EP (4) EP3739060A1 (es)
JP (7) JP5964752B2 (es)
AU (1) AU2010321829B2 (es)
CA (2) CA2776751C (es)
DK (1) DK2504451T3 (es)
ES (1) ES2735993T3 (es)
HU (1) HUE044374T2 (es)
IL (5) IL219051A (es)
MX (3) MX363817B (es)
NZ (1) NZ599194A (es)
PL (1) PL2504451T3 (es)
WO (1) WO2011063274A2 (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
DK2163650T3 (en) 2004-04-09 2015-11-02 Genomic Health Inc Genekspressionsmarkører for prediction of response to chemotherapy
JP5020088B2 (ja) * 2004-11-05 2012-09-05 ジェノミック ヘルス， インコーポレイテッド 遺伝子発現マーカーを使用する、化学療法に対する反応の予測
US7888019B2 (en) 2006-03-31 2011-02-15 Genomic Health, Inc. Genes involved estrogen metabolism
NZ590385A (en) * 2008-06-26 2012-11-30 Dana Farber Cancer Inst Inc Signatures and determinants associated with metastasis and methods of use thereof
US20120041274A1 (en) 2010-01-07 2012-02-16 Myriad Genetics, Incorporated Cancer biomarkers
DK177532B1 (en) 2009-09-17 2013-09-08 Bio Bedst Aps Medical use of sPLA2 hydrolysable liposomes
PL2504451T3 (pl) * 2009-11-23 2019-09-30 Genomic Health, Inc. Sposoby przewidywania wyników klinicznych dla nowotworu
NZ600268A (en) 2010-01-11 2014-08-29 Genomic Health Inc Method to use gene expression to determine likelihood of clinical outcome of renal cancer
GB201009798D0 (en) 2010-06-11 2010-07-21 Immunovia Ab Method,array and use thereof
US20120053253A1 (en) 2010-07-07 2012-03-01 Myriad Genetics, Incorporated Gene signatures for cancer prognosis
ES2925983T3 (es) 2010-07-27 2022-10-20 Genomic Health Inc Método para usar la expresión génica para determinar el pronóstico del cáncer de próstata
EP2611941A4 (en) 2010-08-30 2014-01-22 Myriad Genetics Inc GENESIS OF CANCER DIAGNOSIS AND PROGNOSIS
US8361720B2 (en) 2010-11-15 2013-01-29 Exact Sciences Corporation Real time cleavage assay
US8916344B2 (en) 2010-11-15 2014-12-23 Exact Sciences Corporation Methylation assay
US20140113297A1 (en) * 2011-03-26 2014-04-24 Oregon Health & Science University Gene expression predictors of cancer prognosis
CA2840472A1 (en) * 2011-06-22 2012-12-27 Oncocyte Corporation Methods and compositions for the treatment and diagnosis of bladder cancer
US20140302042A1 (en) * 2011-07-01 2014-10-09 Dana-Farber Cancer Institute, Inc. Methods of predicting prognosis in cancer
KR20140054037A (ko) * 2011-07-13 2014-05-08 더 멀티플 마이얼로머 리서치 파운데이션, 인크. 데이터 수집 및 분배 방법
US20140235486A1 (en) * 2011-08-16 2014-08-21 Oncocyte Corporation Methods and Compositions for the Treatment and Diagnosis of Breast Cancer
SG10202010758SA (en) * 2011-11-08 2020-11-27 Genomic Health Inc Method of predicting breast cancer prognosis
JP5805518B2 (ja) * 2011-12-21 2015-11-04 株式会社島津製作所 マルチプレックス大腸がんマーカーパネル
AU2013215448B2 (en) 2012-01-31 2018-01-04 Mdxhealth Sa Gene expression profile algorithm and test for determining prognosis of prostate cancer
GB201206323D0 (en) * 2012-04-10 2012-05-23 Immunovia Ab Methods and arrays for use in the same
EP2839034A4 (en) * 2012-04-20 2016-01-06 Sloan Kettering Inst Cancer ASSOCIATED GENE EXPRESSION PROFILES ASSOCIATED WITH METASTASISING BREAST CANCER
WO2014055398A1 (en) * 2012-10-05 2014-04-10 Siemens Healthcare Diagnostics Inc. Method for detecting an increased risk or incidence of colorectal cancer
EP2920322B1 (en) 2012-11-16 2023-01-11 Myriad Genetics, Inc. Gene signatures for cancer prognosis
KR101672531B1 (ko) * 2013-04-18 2016-11-17 주식회사 젠큐릭스 조기 유방암 예후 예측 진단용 유전자 마커 및 이의 용도
ES2829415T3 (es) * 2013-05-30 2021-05-31 Genomic Health Inc Algoritmo de perfil de expresión génica para calcular una puntuación de recurrencia para un paciente con cáncer de riñón
US10392667B2 (en) * 2013-06-07 2019-08-27 Medical Prognosis Institute A/S Methods and devices for predicting treatment efficacy of fulvestrant in cancer patients
WO2015138769A1 (en) * 2014-03-12 2015-09-17 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for assessing patients with non-small cell lung cancer
CA2947624A1 (en) 2014-05-13 2015-11-19 Myriad Genetics, Inc. Gene signatures for cancer prognosis
US10184154B2 (en) 2014-09-26 2019-01-22 Mayo Foundation For Medical Education And Research Detecting cholangiocarcinoma
DK3198035T3 (da) 2014-09-26 2023-01-30 Allarity Therapeutics Europe ApS Fremgangsmåder til forudsigelse af medicinrespons
WO2016092299A1 (en) * 2014-12-09 2016-06-16 Medical Research Council Methods and kits for predicting the response to therapy of cancer
CN107532124B (zh) 2015-03-27 2022-08-09 精密科学公司 检测食管疾病
CA3002196C (en) 2015-10-30 2024-05-14 Exact Sciences Development Company, Llc Multiplex amplification detection assay and isolation and detection of dna from plasma
CA3008273A1 (en) 2015-12-18 2017-06-22 Clear Gene, Inc. Methods, compositions, kits and devices for rapid analysis of biological markers
WO2018048354A1 (en) 2016-09-07 2018-03-15 Agency For Science, Technology And Research A method of identifying risk of cancer and therapeutic options
US9725769B1 (en) 2016-10-07 2017-08-08 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
AU2017258901A1 (en) 2016-12-30 2018-07-19 Allarity Therapeutics Europe ApS Methods for predicting drug responsiveness in cancer patients
AU2018211956B2 (en) 2017-01-27 2024-06-20 Exact Sciences Corporation Detection of colon neoplasia by analysis of methylated DNA
WO2018212192A1 (ja) * 2017-05-18 2018-11-22 京都府公立大学法人 癌の予後及び／又は転移可能性を評価する方法及びマーカー
US12275994B2 (en) * 2017-06-22 2025-04-15 Clear Gene, Inc. Methods and compositions for the analysis of cancer biomarkers
KR102424222B1 (ko) 2017-11-13 2022-07-21 더 멀티플 마이얼로머 리서치 파운데이션, 인크. 통합된, 분자, 체학, 면역요법, 대사, 후성적, 및 임상 데이터베이스
US10648025B2 (en) 2017-12-13 2020-05-12 Exact Sciences Development Company, Llc Multiplex amplification detection assay II
AU2019230200A1 (en) * 2018-03-08 2020-10-29 University Of Notre Dame Du Lac Systems and methods for assessing colorectal cancer molecular subtype and risk of recurrence and for determining and administering treatment protocols based thereon
JP7199045B2 (ja) * 2018-04-13 2023-01-05 国立大学法人大阪大学 乳癌の予後に関する情報の取得方法、乳癌の予後の判定装置及びコンピュータプログラム
WO2020059850A1 (ja) * 2018-09-21 2020-03-26 国立大学法人東京大学 がんの予後判定方法
JP2019032334A (ja) * 2018-10-03 2019-02-28 イムノヴィア・アクチエボラーグ 乳癌関連の疾患状態を決定する方法およびこの方法における使用のためのアレイ
KR102216645B1 (ko) * 2018-10-29 2021-02-17 사회복지법인 삼성생명공익재단 폐암의 분자 아형 결정을 위한 바이오마커 패널 및 이의 용도
JP2022512152A (ja) * 2018-12-08 2022-02-02 ピーエフエス・ジェノミクス・インコーポレイテッド 乳がんの予後についてのトランスクリプトームプロファイリング
US20220267855A1 (en) * 2019-05-03 2022-08-25 Dcgen Co, Ltd. A Method for Predicting Prognosis of Cancer and the Composition Thereof
CN111235270B (zh) * 2019-08-29 2022-04-29 北京臻知医学科技有限责任公司 一种基于高通量测序法的肿瘤抗原表达检测引物及试剂盒
US12165747B2 (en) * 2020-01-23 2024-12-10 The Broad Institute, Inc. Molecular spatial mapping of metastatic tumor microenvironment
CA3210972A1 (en) * 2021-02-12 2022-08-18 Mammogen, Inc. Biomarkers for the diagnosis of breast cancer
WO2022192128A2 (en) * 2021-03-08 2022-09-15 Castle Biosciences, Inc. Determining prognosis and treatment based on clinical-pathologic factors and continuous multigene-expression profile scores
CN117116345B (zh) * 2023-07-24 2025-09-16 中国人民解放军军事科学院军事医学研究院 一种基于基因调控网络构建患者生存网络的方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7171311B2 (en) * 2001-06-18 2007-01-30 Rosetta Inpharmatics Llc Methods of assigning treatment to breast cancer patients
EP1410011B1 (en) * 2001-06-18 2011-03-23 Rosetta Inpharmatics LLC Diagnosis and prognosis of breast cancer patients
WO2003004989A2 (en) * 2001-06-21 2003-01-16 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
EP3115470B1 (en) * 2002-03-13 2018-07-18 Genomic Health, Inc. Gene expression profiling in biopsied tumor tissues
US20040067234A1 (en) * 2002-07-11 2004-04-08 Paz Einat Isocitrate dehydrogenase and uses thereof
US20040231909A1 (en) * 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
EP1644858B1 (en) * 2003-07-10 2017-12-06 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
US8019552B2 (en) * 2004-03-05 2011-09-13 The Netherlands Cancer Institute Classification of breast cancer patients using a combination of clinical criteria and informative genesets
CA2582739A1 (en) * 2004-09-30 2006-04-13 Bayer Healthcare Ag Methods and kits for the prediction of therapeutic success and recurrence free survival in cancer therapy
EP1863930A2 (en) * 2005-04-01 2007-12-12 NCC Technology Ventures Pte Limited Materials and methods relating to breast cancer classification
WO2006133460A2 (en) * 2005-06-09 2006-12-14 Yale University Methods for diagnosing and treating breast cancer based on a her/er ratio
WO2006135886A2 (en) * 2005-06-13 2006-12-21 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
CA2612021A1 (en) * 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
TWI304443B (en) * 2005-12-30 2008-12-21 Nat Health Research Institutes Alpha-enolase specific antibody and method of use
US7888019B2 (en) * 2006-03-31 2011-02-15 Genomic Health, Inc. Genes involved estrogen metabolism
AU2008264893A1 (en) * 2007-04-16 2008-12-24 Inserm- Institut National De La Sante Et De La Recherche Medicale Methods of assessing a propensity of clinical outcome for a female mammal suffering from breast cancer
WO2008150512A2 (en) * 2007-06-04 2008-12-11 University Of Louisville Research Foundation, Inc. Methods for identifying an increased likelihood of recurrence of breast cancer
WO2009095319A1 (en) * 2008-01-28 2009-08-06 Siemens Healthcare Diagnostics Gmbh Cancer prognosis by majority voting
WO2009132928A2 (en) * 2008-05-02 2009-11-05 Siemens Healthcare Diagnostics Gmbh Molecular markers for cancer prognosis
DK2294215T3 (da) * 2008-05-12 2013-04-22 Genomic Health Inc Tests til forudsigelse af cancerpatienters respons på forskellige kemoterapeutiske behandlingsmuligheder
PL2504451T3 (pl) * 2009-11-23 2019-09-30 Genomic Health, Inc. Sposoby przewidywania wyników klinicznych dla nowotworu

Also Published As

Publication number Publication date
AU2010321829B2 (en) 2015-07-30
NZ599194A (en) 2014-07-25
JP2022166064A (ja) 2022-11-01
JP2022169647A (ja) 2022-11-09
IL219051A0 (en) 2012-06-28
EP2504451A2 (en) 2012-10-03
EP4350001A3 (en) 2024-06-19
IL276487B (en) 2022-03-01
JP2021058207A (ja) 2021-04-15
IL276487A (en) 2020-09-30
US20190241967A1 (en) 2019-08-08
JP2018196385A (ja) 2018-12-13
CA3043089A1 (en) 2011-05-26
EP4350001A2 (en) 2024-04-10
JP2016214245A (ja) 2016-12-22
JP2024037948A (ja) 2024-03-19
PL2504451T3 (pl) 2019-09-30
MX2012005822A (es) 2012-06-19
JP7042717B2 (ja) 2022-03-28
MX363817B (es) 2019-04-04
EP3739060A1 (en) 2020-11-18
ES2735993T3 (es) 2019-12-23
MX391499B (es) 2025-03-21
JP2013514058A (ja) 2013-04-25
US20210062275A1 (en) 2021-03-04
AU2010321829A1 (en) 2012-05-03
US20110123990A1 (en) 2011-05-26
CA2776751C (en) 2019-07-02
IL264072B (en) 2020-08-31
WO2011063274A3 (en) 2014-03-27
WO2011063274A2 (en) 2011-05-26
IL249159A0 (en) 2017-01-31
IL264072A (en) 2019-02-28
EP2504451A4 (en) 2016-07-06
EP3556867A1 (en) 2019-10-23
EP2504451B1 (en) 2019-06-05
IL219051A (en) 2016-12-29
HUE044374T2 (hu) 2019-10-28
IL257063B (en) 2019-01-31
CA2776751A1 (en) 2011-05-26
US20170211154A1 (en) 2017-07-27
JP5964752B2 (ja) 2016-08-03
MX337650B (es) 2016-03-14
DK2504451T3 (da) 2019-08-05

Similar Documents

Publication Publication Date Title
MX2019003811A (es) Metodos para predecir el desenlace clinico del cancer.
Reddy et al. Readmission after pancreatectomy for pancreatic cancer in Medicare patients
Louie et al. Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis
AR099883A1 (es) Computadora y métodos relacionados con el diagnóstico de cáncer de próstata
NZ620799A (en) Molecular diagnostic test for cancer
MX357402B (es) Metodo para predecir el pronostico de cancer de mama.
MX2019007814A (es) Algoritmo de perfil de expresion genica y prueba para determinar la prognosis de cancer de prostata.
WO2011038011A3 (en) Diagnostician customized medical diagnostic apparatus using a digital library
EA201071319A1 (ru) Генетические маркеры контролирования массы и способы их применения
MX2020001156A (es) Metodo para el pronostico y tratamiento de metastasis de cancer.
CR9315A (es) Metodos y sistemas para el diagnostico, pronostico y seleccion del tratamiento de la leucemia
Deshpande et al. Development of a claims-based algorithm to identify colorectal cancer recurrence
BR112014013444A2 (pt) método para identificar um tecido suspeito como um tecido com câncer; meio de armazenamento não transitório armazenando instruções executáveis por um dispositivo de processamento de dados eletrônicos; e aparelho
BR112013004983A2 (pt) método para a identificação e/ou monitoramento de câncer em um indivíduo, agente de formação de imagem in vivo, e , uso do mesmo
Wells et al. Evolving paradigm for imaging, diagnosis, and management of DCIS
GB201114909D0 (en) Biomarkers for lysosomal storage disorders
MX2012001464A (es) Sensibilidad a inhibidores de la angiogenesis.
Cohen et al. The reflux symptom index--a clinical tool for the diagnosis of laryngopharyngeal reflux
UY31535A1 (es) Método para diagnosticar tumores colorrectales
RU2015124349A (ru) Способ дооперационного прогнозирования стадии и агрессивности рака предстательной железы
Torvinen-Kiiskinen et al. Antidepressant use associated with increased risk of hip fracture in the older
UA95625U (uk) Спосіб прогнозування зрощення перелому
Ferracin Progetto triennale AIRC (MFAG 2011). Titolo: Circulating microRNAs as cancer-specific biomarkers
Sinha Quantifying outcomes after hospital care in England
Rossi et al. Thyroid Nodule Screening for Malignancy: A Prospective Study on Ultrasonographic/Clinical Profile, Cytology and BRAF V600E Mutation Evaluation